...Retrophin, which Martin Shkreli founded in 2011, is now turning its focus to renal candidate sparsentan...

...II Bristol-Myers Squibb Co. (NYSE:BMY) / Ligand Pharmaceuticals Inc. (NASDAQ:LGND) / Retrophin Inc. (NASDAQ:RTRX) Sparsentan (RE-021...

...or 200, 400 or 800 mg oral sparsentan. In patients who received mid- or high-dose sparsentan...
...individual sparsentan doses “showed clear signals of relative improvement, but did not reach statistical significance.” Sparsentan...
...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Sparsentan ( RE-021 ) (formerly PS433540 , BMS-456567...

...combined data from the three cohorts of the Phase II DUET study showed sparsentan ( RE-021...
...often leads to end-stage renal disease. Patients who received 200, 400 and 800 mg oral sparsentan...
...AGTR1 ) antagonist commonly prescribed to treat FSGS and proteinurea (p=0.006). Retrophin said the individual sparsentan...

...results this quarter from the Phase II DUET trial of Retrophin Inc .'s sparsentan ( RE-021...
...3Q16; 10/30/16 Retrophin Inc. (NASDAQ:RTRX) / Ligand Pharmaceuticals Inc. (NASDAQ:LGND) / Bristol-Myers Squibb Co. (NYSE:BMY) Sparsentan...

...eligible to receive RE-021 in an open-label extension. Retrophin has an exclusive, worldwide sublicense to RE-021...
...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Sparsentan ( RE-021 ) (formerly PS433540 , BMS-456567...

...Retrophin Inc. , which Schwarz said "not many investors have on their radar." Lead program RE-021...

...commercialize an autism and schizophrenia product. Details are not disclosed. Retrophin's most advanced product is RE-021...

...to develop and commercialize a product for autism and schizophrenia. Retrophin's most advanced product is RE-021...
...to evaluate RE-021 to treat focal segmental glomerulosclerosis. Retrophin has an exclusive, worldwide sublicense to RE-021...

...to develop and commercialize a product for autism and schizophrenia. Retrophin's most advanced product is RE-021...
...to evaluate RE-021 to treat focal segmental glomerulosclerosis. Retrophin has an exclusive, worldwide sublicense to RE-021...